Duek et al., 2019 - Google Patents
Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared …Duek et al., 2019
View PDF- Document ID
- 17767864816552881951
- Author
- Duek A
- Trakhtenbrot L
- Amariglio N
- Benyamini N
- Zilbershats I
- Ganzel C
- Shevetz O
- Leiba R
- Rozic G
- Nagler A
- Leiba M
- Publication year
- Publication venue
- Genes, Chromosomes and Cancer
External Links
Snippet
The current study evaluated the prognostic significance of the monoallelic deletion of the whole locus of the immunoglobulin heavy‐chain (w_del (IGH)) gene compared to translocations t (4; 14) and t (14; 16) among newly diagnosed multiple myeloma (MM) …
- 206010035226 Plasma cell myeloma 0 title abstract description 45
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Low et al. | Breast cancer: The translation of big genomic data to cancer precision medicine | |
| Lehmann et al. | TBCRC 032 IB/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer | |
| Goschzik et al. | Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial | |
| Giltnane et al. | Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance | |
| Colomo et al. | Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma | |
| Farren et al. | Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy | |
| Oh et al. | Genetic alterations in gliosarcoma and giant cell glioblastoma | |
| Erdem-Eraslan et al. | Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy: a report from the BELOB trial | |
| Buitenkamp et al. | Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations | |
| Chang et al. | Multiple myeloma patients with CKS1B gene amplification have a shorter progression‐free survival post‐autologous stem cell transplantation | |
| Murnyák et al. | PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma | |
| Koutras et al. | Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab | |
| Hobbs et al. | Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas | |
| Harris et al. | Association of nuclear localization of a long interspersed nuclear element-1 protein in breast tumors with poor prognostic outcomes | |
| Long et al. | Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration | |
| Loibl et al. | Integrated analysis of PTEN and p4EBP1 protein expression as predictors for pCR in HER2-positive breast cancer | |
| Angori et al. | Papillary renal cell carcinoma: current and controversial issues | |
| Kim et al. | Association between deficient mismatch repair system and efficacy to irinotecan‐containing chemotherapy in metastatic colon cancer | |
| Cortot et al. | KRAS mutation status in primary nonsmall cell lung cancer and matched metastases | |
| Shi et al. | Single nucleotide polymorphisms in the 20q13 amplicon genes in relation to breast cancer risk and clinical outcome | |
| Ouchi et al. | DNA methylation status as a biomarker of anti‐epidermal growth factor receptor treatment for metastatic colorectal cancer | |
| Gadd et al. | Genetic changes associated with relapse in favorable histology Wilms tumor: A Children’s Oncology Group AREN03B2 study | |
| Kleinstern et al. | Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B‐cell lymphocytosis beyond the CLL international prognostic index | |
| Ter Brugge et al. | Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers | |
| Kim et al. | Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy |